Mary Ellen Hackett
Manager, Communications Office
Email maryellen.hackett@nih.gov or call 301-401-8670 for all media related questions.
Featured News
All News
Inhibition of the MAPK pathway induces re-localization of membranous proteins, leading to adaptive resistance to KRAS G12C inhibitor mediated by YAP-induced MRAS
While promising and exciting, the new KRAS G12C inhibitors have been met with unknown mechanisms of resistance. Here, Yuta Adachi and Hiromichi Ebi describe their work uncovering a non-genetic resistance mechanism involving the mis-localization of scribble, which induces YAP-mediated MRAS expression and reactivates MAPK signaling.POSTED: 11/1/2023
New type of bifunctional molecules perturb K-Ras interactions with membranes
Drs. Kevan Shokat and Johannes Morstein and describe their new and unique bifunctional drugs that bind to both KRAS and the plasma membrane.POSTED: 9/28/2023
KRAS somatic cancer-driver mutations in endometriosis without cancer: towards a molecular classification for endometriosis?
KRAS mutations are not only found in cancer—discover how this cancer driver is also mutated in endometriosis, and what that means for diagnosis.POSTED: 9/6/2023
Oncogene turned bystander - How molecular context shapes KRas oncogenicity
Why do KRAS mutations drive cancers in some tissues and not others? Drs. Olesja Popow and Kevin Haigis share their insight into this persistent question.POSTED: 7/21/2023
RAS Chat: An Interview with Kevan Shokat and Ziyang Zhang
Join us for a conversation with RAS heavy hitters Kevan Shokat and Ziyang Zhang as they reflect on how far the field has come, discuss current projects, and share what they’re most excited about for the future.POSTED: 6/26/2023
Consensus on the RAS Dimerization Hypothesis
Does RAS really form dimers? Drs. John Hancock, Mark Philips, and Dhirendra Simanshu discuss this hotly debated topic.POSTED: 5/2/2023
KRASG12C inhibition drives anti-tumour immunity in lung cancer but combinations with anti-PD1 immunotherapy may only benefit patients with ‘inflamed’ tumours
KRASG12C inhibitors not only shrink tumors but also unleash anti-tumor immunity—could this be the key to transforming “cold” tumors into immunotherapy wins?POSTED: 11/14/2022
The use of Molecular Docking as a ligand discovery tool; Can machine learning help the pursuit for ligands?
Will AI revolutionize the way we develop new chemotherapies? Join me for a conversation with machine-learning expert Dr. Trent Balius to find out.POSTED: 7/6/2022
Could CryoEM structures of neurofibromin lead the way to better therapeutic approaches for Neurofibromatosis type 1?
Recent breakthroughs in our understanding of neurofibromin structure shed light on how mutations disrupt the proteins’ structure and function. Will this change the game in the fight against Neurofibromatosis type 1?POSTED: 5/18/2022